Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

By                    

Oncology Letters, Vol. 2, Iss. 3, 2011-01 ,pp. : 493-498

Spandidos Publications

Access to resources Recommend Favorite

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

By Hebbar Mohamed   Tournigand Christophe   Lledo Gérard   Mabro May   André Thierry   Louvet Christophe   Aparicio Thomas   Flesch Michel   Varette Charles   de Gramont Aimery   Group (GERCOR) Oncology  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 154-159

Informa Healthcare

Access to resources Recommend Favorite

Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

By Hebbar Mohamed  

Journal of Chemotherapy, Vol. 25, Iss. 2, 2013-04 ,pp. : 104-111

Maney Publishing

Access to resources Recommend Favorite

XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1864-1872

Spandidos Publications

Access to resources Recommend Favorite

FOLFOX-4 Regimen with Concomitant Highly Active Antiretroviral Therapy in Metastatic Colorectal Cancer HIV-Infected Patients: A Report of Five Cases and Review of the Literature

By Berretta Massimiliano   Di Benedetto Fabrizio   Bearz Alessandra   Simonelli Cecilia   Martellotta Ferdinando   Del Ben Chiara   Berretta Salvatore   Spina Michele   Tirelli Umberto  

Cancer Investigation, Vol. 26, Iss. 6, 2008-07 ,pp. : 610-614

Informa Healthcare

Access to resources Recommend Favorite